

and independent association with endothelial vasomotor dysfunction in the conduit and resistance vessels in the coronary circulation in normotensive as well as hypertensive patients. Increased ambulatory PP may have an intimate relation to coronary endothelial vasomotor dysfunction.

Reprint requests and correspondence: Dr. Kiyotaka Kugiyama, Department of Internal Medicine II, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Nakakoma-gun, Yamanashi, 409-3898 Japan. E-mail: kugiyama@yamanashi.ac.jp.

REFERENCES

1. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart study. *Circulation* 2001;103:1245-9.
2. Safar ME. Pulse pressure, arterial stiffness, and cardiovascular risk. *Curr Opin Cardiol* 2000;15:258-63.
3. Ceravolo R, Maio R, Pujia A, et al. Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. *J Am Coll Cardiol* 2003;41:1753-8.
4. Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med* 1997;157:2413-46.
5. Kugiyama K, Doi H, Motoyama T, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. *Circulation* 1998;97:2519-26.
6. Iida T, Kohno I, Fujioka D, et al. Blunted reduction of pulse pressure during nighttime is associated with left ventricular hypertrophy in elderly hypertensive patients. *Hypertens Res* 2004;27:573-9.
7. Ijiri H, Kohno I, Yin D, et al. Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension. *Jpn Circ J* 2000;64:499-504.
8. Staessen JA, Thijs L, O'Brien ET, et al. Ambulatory pulse pressure as predictor of outcome in older patients with systolic hypertension. *Am J Hypertens* 2002;15:835-43.
9. White WB, Grin JM, McCabe EJ. Clinical usefulness of ambulatory blood pressure monitoring. *Am J Hypertens* 1993;6:225S-8S.
10. Nakamura S, Sugiyama S, Fujioka D, Kawabata K, Ogawa H, Kugiyama K. Polymorphism in glutamate-cysteine ligase modifier subunit gene is associated with impairment of nitric oxide-mediated coronary vasomotor function. *Circulation* 2003;108:1425-7.
11. Kugiyama K, Yasue H, Ohgushi M, et al. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. *J Am Coll Cardiol* 1996;28:1161-7.
12. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. *Circulation* 1996;94:266-71.
13. Griendling KK, Alexander RW. Endothelial control of the cardiovascular systems: recent advance. *FASEB J* 1996;10:283-92.
14. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. *Circulation* 2003;107:2864-9.
15. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. *Am J Hypertens* 1999;12:205S-13S.

Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis

Katsunori Ikewaki, Juergen R. Schaefer, Michael E. Frischmann, Keio Okubo, Tatsuo Hosoya, Seibu Mochizuki, Benjamin Dieplinger, Evi Trenkwalder, Horst Schweer, Florian Kronenberg, Paul Koenig, Hans Dieplinger

Objective—Premature cardiovascular disease is the leading cause of death in patients with end-stage renal disease treated by hemodialysis (HD). Low-density lipoprotein (LDL) levels are not generally increased in HD patients, but their LDL metabolism is still poorly understood. We therefore investigated the in vivo metabolism of apoB-containing lipoproteins in two different ethnic populations of HD patients and controls.

Methods and Results—We performed stable isotope kinetic studies using a primed constant infusion of deuterated leucine in 12 HD patients and 13 healthy controls. Tracer/tracee ratio of apoB was determined by means of gas chromatography/mass spectrometry, and the modeling program SAAMII was used to estimate the fractional catabolic rate (FCR) of apoB. Mean LDL-apoB plasma concentrations were almost identical in both groups (HD: 95 ± 30 mg/dL, controls: 91 ± 40 mg/dL), whereas LDL-apoB FCR was 50% lower in HD patients as compared with controls (0.22 ± 0.12 days⁻¹ versus 0.46 ± 0.20 days⁻¹, $P=0.001$) with concomitantly decreased production rates of LDL. Compared with controls, intermediate-density lipoprotein (IDL)-apoB FCR was 65% lower (2.87 ± 1.02 days⁻¹ versus 8.89 ± 4.94 days⁻¹, $P=0.014$), accompanied by 1.5-fold higher IDL-apoB levels in HD. Very low-density lipoprotein metabolism was similar in both study groups.

Conclusions—In vivo catabolism of LDL and IDL is severely impaired in HD patients but misleadingly masked by normal plasma cholesterol levels. The resulting markedly prolonged residence times of both IDL and LDL particles might thus significantly contribute to the well-documented high risk for premature cardiovascular disease in HD patients. (*Arterioscler Thromb Vasc Biol.* 2005;25:2615-2622.)

Key Words: cardiovascular diseases ■ isotopes ■ kidney ■ lipoproteins ■ metabolism

Thirty years ago, Lindner and colleagues recognized in their seminal report the excessive risk of cardiovascular disease for hemodialysis (HD) patients.¹ The prevalence and incidence of cardiovascular disease is much higher in HD patients, and current mortality rates are ≈ 10 to 20 times greater than the general population with rates even higher at young ages.² A remarkable number of factors, including dyslipoproteinemia, chronic inflammation, hypertension, oxidative stress, elevated homocysteine, and anemia, that may contribute to this increased frequency of atherosclerotic complications have been identified.^{3,4}

HD patients are characterized by a complex plasma dyslipoproteinemic profile.⁵ The most notable quantitative abnor-

malities are elevated plasma triglyceride and very low-density lipoprotein (VLDL) levels with a prevalence of 25% to 75%,^{6,7} increased levels of atherogenic intermediate density lipoprotein (IDL)⁸ and lipoprotein(a)⁹ particles, and decreased high-density lipoprotein (HDL) levels.¹⁰ Interestingly, total and low-density lipoprotein (LDL) cholesterol plasma levels are usually normal or even subnormal in HD patients as compared with healthy controls.^{11,12}

In addition to quantitative changes in lipoprotein particles, numerous compositional and qualitative lipoprotein changes have been demonstrated as well. These include accumulation of small dense LDL¹³ as well as oxidation, glycation, and carbamylation of LDL. The association of small dense LDL

Original received June 17, 2005; final version accepted September 13, 2005.

From the Divisions of Cardiology (K.I., S.M.) and Nephrology (K.O., T.H.), Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan; the Department of Internal Medicine—Cardiology (J.R.S.) and Children's Hospital (H.S.), Philipps University, Marburg, Germany; the Division of Genetic Epidemiology (M.E.F., E.T., F.K., H.D.), Department of Medical Genetics, Clinical and Molecular Pharmacology and the Department of Clinical Nephrology (P.K.), Innsbruck Medical University, Innsbruck, Austria; the Department of Laboratory Medicine (B.D.), Konventhospital Barnherzige Brueder, Linz, Austria; and the Institute of Epidemiology (F.K.), GSF-National Research Center for Environment and Health, Neuherberg, Germany.

*Drs Ikewaki and Schaefer contributed equally to this article.

Correspondence to Hans Dieplinger, Division of Genetic Epidemiology, Department of Medical Genetics, Clinical and Molecular Pharmacology, Innsbruck Medical University, Schoepfstrasse 41, A-6020 Innsbruck, Austria. E-mail hans.dieplinger@i-med.ac.at

© 2005 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol. is available at <http://www.atvbaha.org>

DOI: 10.1161/01.ATV.0000188555.60475.c2

with increased risk for cardiovascular disease in the general population has been controversially discussed.¹⁴ The abnormal lipid composition of all lipoprotein classes has been reported to be caused mainly by a combination of an impaired reversed cholesterol transport¹¹ and lipolytic cascade.¹⁵

To date, only 2 apoB kinetic studies have been reported in HD patients: Chan et al injected radio-labeled VLDL into HD patients with or without hyperlipidemia and found decreased fractional catabolic rates (FCR) of VLDL- and IDL-apoB (the latter only in hyperlipidemic patients).¹⁶ Unfortunately, the LDL turnover was not investigated in this study. Hörrkö et al injected radio-labeled LDL and observed a decreased LDL-apoB clearance in renal patients treated with peritoneal dialysis but not in HD patients.¹⁷ Overall, the exact underlying metabolic abnormalities of apoB-containing lipoproteins in HD patients are far from clear. LDL-apoB kinetic studies in predialysis patients with chronic kidney disease have yielded controversial results; radiotracer studies reported decreased LDL clearance rates,¹⁸ whereas more recent studies using stable isotopes found unchanged FCR values for LDL-apoB in these patients.¹⁹

To resolve the apparent discrepancy between an obviously impaired lipoprotein metabolism and normal LDL plasma concentrations in HD patients, we independently studied the *in vivo* kinetics of apoB-containing particles in Austrian and Japanese HD patients and healthy controls using stable isotope technology. This study demonstrates for the first time significantly increased residence times of the most atherogenic lipoproteins IDL and LDL (despite normal levels of the latter) and might help explain the extremely high prevalence of cardiovascular disease in these patients.

Subjects and Methods

Study Design

The two kinetic studies followed corresponding protocols previously described^{20–22} and approved by the Internal Review Boards of the Philipps University of Marburg, Germany, the Innsbruck Medical University, Austria, and the Jikei University School of Medicine, Tokyo, Japan. Informed, written consent was obtained from each study participant before the study. The study was performed in all HD patients 1 day after dialysis. For 3 days preceding the study, all study participants received a standardized isocaloric diet composed of 30 kcal/kg body weight, 50% carbohydrates, 30% fat, and 20% protein with a maximum of 300 mg cholesterol/d. After starting following a ten-hour overnight fasting period, all study participants maintained their fast during the first 12 hours of the study. Two plastic indwelling catheters were placed intravenously in contralateral arm veins: one catheter was used for the tracer infusion and the other was used for the frequent blood sampling during the study. Trideuterated L-leucine (99% pure; Cambridge Isotopes Laboratories Inc) was administered as a priming bolus of 1.34 and 1.00 mg/kg for Austrian and Japanese study subjects, respectively, followed immediately by a constant infusion of 22 (Austrian) or 17 (Japanese) $\mu\text{g}/\text{kg}$ per min for up to 12 hours. Blood samples (9 mL) were drawn into tubes containing EDTA (1 g/L) before tracer injection 10, 20, 30, 40, 60, 90, and 120 minutes thereafter, then hourly for up to 12 hours and daily for up to 1 week. Plasma was obtained by low-speed centrifugation and kept on ice until use.

Study Participants

A total of 12 male end-stage renal disease (ESRD) patients treated with HD (7 Austrians and 5 Japanese) and 13 male healthy controls (9 Austrians and 4 Japanese, selected from university and hospital

staff) were studied. The mean age of HD patients was 51 ± 13 years, whereas the age of healthy control subjects was 35 ± 10 years. Dialysis was performed 3 times weekly for 4 hours on average. Dialysis adequacy was monitored monthly by calculating Kt/V values. In case of falling below a value of 1.2, dialysis session length was increased accordingly resulting in a value of 1.3 in 10 and 1.2 in 2 patients. HD patients had been dialyzed for an average of 66 months before the study. None of the study subjects had diabetes mellitus or any history of cardiovascular disease, familial hyperlipidemia, and nephrotic syndrome affecting the lipid metabolism at the time of this study. HD patients took vitamins, erythropoietin, and bicarbonate but had never received any lipid-lowering medication. The primary reason for developing ESRD as well as further clinical characteristics of all subjects are summarized in Table 1.

Preparation of Lipoproteins and Apolipoproteins

VLDL ($d < 1.006$ g/mL), IDL ($d = 1.006$ to 1.019 g/mL), and LDL ($d = 1.019$ to 1.063 g/mL) were isolated by sequential preparative ultracentrifugation from 5 mL of plasma (50.3 Ti rotor, L-70K centrifuge; Beckman Instruments). VLDL-apoB, IDL-apoB, and LDL-apoB were isolated by preparative 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions. IDL were not collected from the Austrian study group.

Determination of Isotopic Enrichment

Apolipoprotein bands were excised from gels, hydrolyzed in 6 mol/L HCl at 110°C for 24 hours under nitrogen and lyophilized. Free amino acids were purified from plasma or protein hydrolysates by cation exchange chromatography (AG-50W-X6; Bio-Rad Laboratories) and then derivatized to *n*-heptafluorobutyrylisobutyl esters and, in the Austrian study, analyzed by gas chromatography/triple-stage quadrupole mass spectrometry in the chemical ionization and selected ion-monitoring mode, as previously reported.²³ The ions monitored were 363.1 *m/z* (mass-to-charge ratio) for unlabeled L-leucine and 366.1 *m/z* for labeled [2H3] L-leucine as parent ions (first mass spectrometry [MS]) and 280.1 *m/z* for the daughter ions of both types of leucine (second MS). In the Japanese study, isotopic enrichment was analyzed by gas chromatography (GC)-MS on a 6890 gas chromatograph connected to a 5973 quadrupole mass spectrometer (Hewlett Packard). Tracer enrichment was calculated as the tracer-to-tracee ratio, which is equivalent to the specific activity in radiotracer studies.²⁴

Kinetic Modeling

A multicompartmental model was built using an interactive computer program (SAAMII, version 1.1; SAAM Institute Inc)²⁵ to determine apoB kinetic parameters. A previously published compartmental model²⁶ was used as the template for this study. Briefly, the plasma amino acid pool (compartment 1) was used as a forcing function, followed by a delay compartment (compartment 2) for lipoprotein assembly and subsequent secretion of lipoproteins from the liver. A single compartment was allocated for VLDL (compartment 3), IDL (compartment 4), and LDL (compartment 5). In the Austrian study group, the IDL compartment was excluded attributable to the lack of IDL data.

Individual percentage changes in plasma concentrations of VLDL-, IDL- and LDL-apoB, triglycerides, total and HDL-cholesterol were within 5% throughout the study period (data not shown), indicating steady state conditions. Therefore, the FCR was assumed to be equal to the fractional synthetic rate. Residence time equals $1/\text{FCR}$. Fractional standard deviations, which equal the coefficient of variation of the respective parameter, for apoB FCR provided reasonable levels; the mean fractional standard deviation was $11.4 \pm 6.5\%$ for VLDL-apoB, $18.3 \pm 17.2\%$ for IDL-apoB, and $7.4 \pm 5.2\%$ for LDL-apoB.

Because plasma volume (PV) has been shown to be increased in HD patients,^{27–29} we adjusted PV values by hematocrit (Hct) using a recently reported formula by Mitra et al³⁰ ($\text{PV} = \text{blood volume} [\text{BV}] \cdot [1 \text{ to } 0.86 \cdot \text{Hct}]$). The factor 0.86 corrects for the difference between Hct levels in the systemic circulation and whole-body Hct

TABLE 1. Clinical Characteristics of HD Patients and Control Subjects

Subjects	Age, y	BMI, kg/m ²	Hct	Prot, g/dl	Alb, g/dl	CRP, mg/l	ApoE	Chol, mg/dl	LDL-C, mg/dl	HDL-C, mg/dl	TG, mg/dl	ApoB, mg/dl	Cause ESRD	Durat HD, mo	Creat, mg/dl	Urea, mg/dl
Controls																
1	27	22.3	0.37	6.5	4.2	1.9	3/3	141	90	34	86	66				
2	32	24.2	0.45	7.4	4.5	4.0	3/3	299	240	41	91	194				
3	50	27.6	0.48	5.8	3.6	5.8	4/3	204	125	36	216	125				
4	28	21.0	0.42	6.4	3.9	2.1	3/3	99	52	31	79	43				
5	36	30.6	0.45	7.0	4.8	1.0	4/3	196	126	45	124	116				
6	43	25.4	0.46	6.3	4.0	2.0	3/3	170	117	42	57	98				
7	23	22.5	0.45	6.5	4.1	2.0	2/2	150	93	37	100	150				
8	42	24.6	0.49	7.0	4.0	0.1	3/3	154	92	52	50	97				
9	21	22.0	0.45	7.0	4.4	0.1	3/3	187	113	56	90	94				
10	48	23.3	0.44	7.2	4.1	0.3	3/3	183	109	51	117	83				
11	45	22.9	0.45	7.3	4.2	0.9	3/3	173	107	49	86	85				
12	40	20.9	0.44	7.4	4.5	0.1	3/3	160	97	45	87	75				
13	23	22.0	0.45	8.4	5.3	0.1	3/3	182	100	59	113	79				
Patients																
1	31	26.5	0.34	6.7	3.9	4.7	3/3	184	129	27	140	163	GP	75	13.4	193
2	60	21.0	0.34	6.6	3.7	8.0	3/3	194	136	45	63	102	RAS	27	9.0	63
3	33	20.6	0.33	6.7	4.2	2.0	3/2	126	72	29	127	100	PN	108	13.5	170
4	61	22.3	0.33	6.5	3.6	12.0	3/3	168	115	31	111	84	SK	44	13.0	175
5	35	23.5	0.39	6.6	3.9	5.0	4/3	174	117	25	160	97	IgA	5	9.3	146
6	67	18.4	0.30	6.4	3.6	3.3	3/3	262	191	38	166	154	SK	41	9.7	94
7	61	24.5	0.33	7.1	3.7	2.0	3/3	253	168	35	250	163	PN	34	12.4	160
8	60	23.9	0.28	5.6	3.2	4.5	3/3	145	88	38	94	77	CGN	108	8.1	59
9	66	21.4	0.25	6.0	3.2	6.0	3/3	138	75	37	131	80	CGN	3	9.0	55
10	50	23.5	0.29	6.4	3.9	3.0	3/3	151	94	28	142	90	CGN	144	11.3	63
11	45	23.0	0.30	6.4	3.6	2.4	3/3	158	106	28	120	82	CGN	228	13.1	56
12	46	24.6	0.33	6.3	3.9	8.0	4/3	171	118	25	144	114	PKD	228	18.9	89
Controls, Mean±SD	35±10	23.8±2.8	0.45±0.03	6.9±0.7	4.3±0.4	1.6±1.7		177±46	112±43	45±9	100±41	100±39				
Patients, Mean±SD	51±13	22.8±2.2	0.32±0.04	6.4±0.4	3.7±0.3	5.1±3.0		177±42	117±36	32±6	137±45	109±33		66±88	11.7±3.0	110±54
P Value	0.005	0.610	0.000	0.049	0.001	0.001		0.740	0.530	0.002	0.008	0.430				

GP indicates Goodpasture syndrome; RAS, renal arterial stenosis; IgA, IgA nephritis; SK, small kidney; PN, pyelonephritis; CGN, chronic glomerulonephritis; PKD, polycystic kidney disease; CRP, C-reactive protein; Alb, albumin; BMI, body mass index; Chol, cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; TG, triglycerides; ESRD, end-stage renal disease; Creat, creatinine.

Controls: subjects 1 to 9 (whites), subjects 10 to 13 (Japanese); Patients: subjects 1 to 7 (whites), subjects 8 to 12 (Japanese)

levels as well as trapped plasma ($\approx 4\%$). BV is similar between HD patients and controls when normotensive patients are selected.^{31,32} Because patients in the present study were all normotensive, they were considered to have no intravascular fluid expansion. We therefore used 7% as the percentage BV (% BV/body weight) in both HD patients and control subjects.³³ Taken together, production rate (PR, mg/kg per day) was calculated by the formula $PR = FCR \cdot \text{apolipoprotein concentration}_{\text{in plasma}} \cdot (1 \text{ to } 0.86 \cdot \text{Hct}) \cdot 0.07$.

Quantification of Lipids, Apolipoproteins, and Routine Laboratory Parameters

Triglycerides, total cholesterol, and HDL cholesterol were measured with commercially available kits from Roche Diagnostics GmbH. LDL cholesterol was calculated with the Friedewald formula. ApoB concentrations of plasma and fractions thereof were measured by ELISA.³⁴ An affinity-purified polyclonal antibody against apoB

(produced in our laboratory by immunizing rabbits with purified apoB) was used for coating and the same antibody, labeled with horseradish peroxidase, for detection. A calibrated standard (Apo-proteins Human ApoB; Technoclone) served as a secondary standard. ApoE phenotyping was performed on delipidated plasma by isoelectric focusing. Urea, creatinine, total protein, albumin, and C-reactive protein were determined using standard assays on a COBAS INTEGRA analyzer (Roche Diagnostics).

Statistical Analysis

Data are presented as mean±SD, except as noted. For statistical analysis we used the nonparametric Mann-Whitney U test to test for significant differences between groups. Nonparametric correlations were calculated according to Spearman test. Significance is defined as $P < 0.05$.

Results

Clinical Characteristics of HD Patients and Controls

Lipids and lipoprotein profiles of the 12 HD patients and of 13 healthy controls are summarized in Table 1. Total cholesterol, LDL cholesterol, and apoB concentrations were almost identical in both groups. Triglycerides were significantly higher (137 mg/dL versus 100 mg/dL) and HDL cholesterol significantly lower (32 mg/dL versus 45 mg/dL) as compared with controls, which is in accordance with previous findings.¹²

Kinetics of ApoB-Containing Lipoproteins

Figure 1 illustrates the mean tracer/tracee curves of apoB from the Austrian and Japanese studies, respectively. In both study groups, VLDL curves did not differ between HD patients and controls (not shown). In contrast, the LDL tracer/tracee curve increased more slowly in HD patients than in control subjects. In the Japanese study, the tracer/tracee curve of IDL-apoB from HD patients increased slowly, reached a peak around 20 hours, and then slowly decreased. This was in contrast to the control IDL-apoB curve, which peaked around 10 hours and thus closely followed the VLDL apoB tracer/tracee curve, particularly toward the second half of the study period. In line with the results from the Austrian study, the LDL apoB tracer/tracee curve was also slower than the control's counterpart and kept rising during the full study period of 48 hours.

Despite the fact that total cholesterol, LDL cholesterol, and LDL apoB levels were almost identical in HD patients and controls, we found dramatic differences in the *in vivo* kinetic parameters of IDL- and LDL-apoB between both groups, whereas the kinetic parameters of VLDL were not significantly different (Table 2 and Figure 2). Compared with controls, IDL-apoB FCR was one-third as high (2.87 ± 1.02 versus 8.89 ± 4.94 pools/d, $P=0.014$) in HD patients, accompanied by a 24% decrease in PR (9.05 ± 3.08 versus 11.84 ± 4.42 mg/kg-day) which did not, however, reach statistical significance ($P=0.221$). This resulted in a 60% increase in IDL-apoB levels in HD patients (6.2 ± 1.8 versus 3.9 ± 2.7 mg/dL). LDL-apoB FCR was significantly decreased to 50% in HD patients as compared with controls (0.22 ± 0.12 versus 0.46 ± 0.20 pools/d), which corresponded to a severely prolonged residence time of 4.6 days in HD versus 2.2 days in healthy controls. Furthermore, the LDL-apoB PR was significantly decreased in HD as compared with controls (9.8 ± 4.9 versus 18.4 ± 13.3 mg/kg-day).

Discussion

The major outcome of this study is the elucidation of an impaired metabolism of atherogenic lipoproteins which might significantly contribute to the high rate of cardiovascular disease in HD. We studied for the first time the *in vivo* kinetics of the atherogenic lipoproteins VLDL, IDL, and LDL in HD patients using stable isotope-labeling technology. Interestingly, the FCRs of IDL and LDL apoB were severely decreased in HD patients as compared with controls, whereas the *in vivo* kinetics of VLDL did not change significantly.




Figure 1. Tracer/tracee ratio curves for apoB-100 from IDL and LDL. ApoB tracer/tracee ratio curves of IDL and LDL were calculated from Japanese and Austrian HD patients (triangles) and controls (circles). Data were fitted by multicompartmental modeling using SAAMIII. Bars represent standard error of means.

We did not investigate the metabolism of VLDL subfractions separately because it was previously shown in healthy subjects that FCR values of VLDL1 and VLDL2 did not differ from those of total VLDL.^{35,36} We cannot, however, exclude that changes in the subfraction distribution in HD patients could be different compared with controls. Another limitation of the study is the assumption of comparable BVs

TABLE 2. Plasma Concentrations, FCRs, and PRs of VLDL-apoB, IDL-apoB, and LDL-apoB From HD Patients and Control Subjects

Subjects	VLDL-apoB, mg/dl	VLDL-apoB-FCR, days ⁻¹	VLDL-apoB-PR, mg/kg/day	IDL-apoB, mg/dl	IDL-apoB-FCR, days ⁻¹	IDL-apoB-PR, mg/kg/day	LDL-apoB, mg/dl	LDL-apoB-FCR, days ⁻¹	LDL-apoB-PR, mg/kg/day
Controls									
1	4.0	8.47	16.17	n.d.	n.d.	n.d.	48.0	0.242	5.54
2	1.6	24.49	16.81	n.d.	n.d.	n.d.	186.2	0.314	25.12
3	5.2	6.09	13.02	n.d.	n.d.	n.d.	111.6	0.582	26.69
4	0.3	4.39	0.51	n.d.	n.d.	n.d.	41.7	0.563	10.50
5	1.2	8.45	4.24	n.d.	n.d.	n.d.	111.0	0.280	13.33
6	13.5	15.88	90.71	n.d.	n.d.	n.d.	78.4	0.211	7.01
7	3.0	43.56	56.07	n.d.	n.d.	n.d.	143.0	0.929	57.01
8	0.4	7.77	1.26	n.d.	n.d.	n.d.	95.3	0.596	22.99
9	1.5	34.13	21.68	n.d.	n.d.	n.d.	82.5	0.298	10.55
10	6.6	6.00	17.13	6.8	4.66	13.84	68.2	0.527	15.64
11	4.6	10.77	22.57	5.7	6.22	16.16	70.4	0.552	17.75
12	3.2	8.74	12.24	1.7	15.83	11.50	67.8	0.430	12.65
13	3.5	8.21	12.30	1.5	8.86	5.86	72.0	0.480	14.99
Patients									
1	14.5	7.48	53.76	n.d.	n.d.	n.d.	143.1	0.209	14.83
2	0.2	36.50	3.43	n.d.	n.d.	n.d.	92.7	0.199	9.15
3	0.8	10.35	4.15	n.d.	n.d.	n.d.	91.9	0.120	5.53
4	5.7	6.50	18.59	n.d.	n.d.	n.d.	74.2	0.175	6.50
5	5.4	4.35	10.92	n.d.	n.d.	n.d.	83.2	0.077	2.99
6	0.3	8.49	1.32	n.d.	n.d.	n.d.	134.2	0.210	14.64
7	8.2	10.05	41.32	n.d.	n.d.	n.d.	145.9	0.057	4.14
8	4.6	8.49	20.87	5.4	3.93	11.27	68.9	0.449	16.51
9	3.0	6.14	10.11	4.1	3.79	8.58	68.3	0.110	4.13
10	7.0	4.27	15.71	8.1	2.25	9.57	70.3	0.340	12.50
11	6.1	4.83	15.40	5.1	1.52	4.06	69.8	0.380	13.86
12	7.9	3.66	14.58	8.1	2.88	11.79	92.5	0.268	12.50
Controls, Mean±SD	3.7±3.5	14.38±12.18	21.90±24.91	3.9±2.7	8.89±4.94	11.84±4.42	90.5±39.8	0.462±0.197	18.44±13.30
Patients, Mean±SD	5.3±4.0	9.26±8.87	17.51±15.51	6.2±1.8	2.87±1.02	9.05±3.08	94.6±29.7	0.216±0.123	9.77±4.91
P Value	0.221	0.157	0.663	0.327	0.014	0.221	0.550	0.001	0.026

n.d. indicates not determined.

See Table 1 for patient and control subject specifications.

between normotensive HD patients and controls, which is the prerequisite for calculating PV using the formula of Mitra et al.³⁰ Previous investigations, however, have found very minor differences in the relative BV between HD patients and controls.^{32,37} HD results in a relative BV reduction in the range of up to 15% per ultrafiltration cycle.³⁸ Even when suspecting a persistently reduced BV on the interdialytic day (which was our day of investigation), this effect is very unlikely having caused the large difference in PRs of LDL-apoB between patients and controls. The two other kinetic parameters (FCRs and residence times) are independent of parameters' blood concentrations.

Markers for malnutrition and inflammation are widely recognized as predictors for cardiovascular disease in chronic kidney disease.³⁹ Our HD patients did not show signs of inflammation or malnutrition: although their plasma albumin, total protein, and C-reactive protein plasma levels differed significantly from those of controls, they were within normal

range. In fact, plasma levels in HD patients should be corrected for their Hct levels to be accurately comparable to those of healthy controls.²⁷ This calculation would result in even higher mean values for total protein and albumin in HD patients compared with controls. Resulting C-reactive protein values would then still be within normal range (except patient #4 whose kinetic parameters were, nevertheless, all close to the mean levels of the whole patient group).

A decreased FCR for IDL and LDL apoB is identical to an extended residence time of these highly atherogenic particles. The longer residence time of these lipoprotein fractions results in an extended oxidation time of IDL and LDL in a highly oxidative environment. This was in fact experimentally shown by a highly significant correlation of 5-hydroxy-2-aminovaleric acid (HAVA) in LDL, an oxidation product of apoB-100, with the LDL residence time in normolipidemic controls.⁴⁰ In line with these results, two recent randomized placebo-controlled studies revealed a significant reduction in




Figure 2. Kinetic parameters of apoB from LDL. Plasma concentrations of LDL-apoB as well as the respective FCR, residence time and PR values are indicated for HD patients (black columns) and controls (white columns). Bars show standard error of means. Values are expressed for the total study group as well as separately for Austrian and Japanese study groups.

composite cardiovascular disease end points when HD patients were treated for two years with supplementation of antioxidants like vitamin E⁴¹ or acetylcysteine.⁴²

Most remarkably, the observed substantially impaired metabolism of apoB-100-containing lipoproteins is accompanied by normal levels of LDL-apoB and elevated levels of IDL-apoB (Table 2, Figure 2), in line with previous reports which found increased levels of IDL as an independent risk factor for atherosclerosis in HD patients.⁴³

Our kinetic data seem to contrast with a previously published turnover study in Finnish HD patients performed with conventional radiotracer techniques. Although the authors found decreased LDL clearance rates in predialysis patients with chronic kidney failure,¹⁸ they could not find a significant difference in LDL-apoB FCR between their HD patients and controls.¹⁷ The reason for this discrepancy is not clear. There might be ethnic differences in the lipoprotein metabolism between Finns, Austrians, and Japanese although we could not detect substantial differences in our data when stratified into Japanese and Austrian subgroups (Figure 2). FCR and residence time values of LDL-apoB differed significantly between HD patients and controls in both ethnic groups. The differences in PR of LDL-apoB between cases and controls did only reach significance when calculated in the total groups and showed only borderline significance when considered separately for each ethnic group, suggesting limited statistical power with respect to PR values. One major difference to the above-mentioned study is an age difference between patients and controls in our study but not in the Finnish study. Our control subjects were considerably younger than the HD patients (35 versus 51 years). At first glance, this age difference might explain to some extent the dramatic differences found in our study because LDL clearance rates have been repeatedly described to decrease with

age presumably attributable to downregulated hepatic LDL receptor expression in the elderly.^{44,45} Based on the results of these studies, an age difference of 15 years (as observed in our work) would result in an $\approx 10\%$ change in FCR values and could not therefore explain the more than 2-fold difference in our study. Comparative analysis of an age-matched subsample of five patients (subjects 1, 3, 5, 10, and 11, mean age 38.8 years) and controls (subjects 2, 3, 4, 5, and 11, mean age 38.2 years) revealed very similar mean LDL-FCR values (0.225 and 0.458 pools/d, respectively) as compared with the whole study collective. In addition, LDL-apoB FCR did not correlate with age in our study (HD patients: $r = -0.112$, $P = 0.728$; controls: $r = 0.165$, $P = 0.590$), no matter whether the total group or Japanese and Austrian subjects were calculated separately. The observed differences in kinetic parameters therefore cannot be explained by age differences between study groups. Finally, when we reanalyzed the data from the Finnish study, we found 2 HD patients (subjects 10 and 11) who had substantially higher LDL apoB FCR (0.451 and 0.472 pools/d) than did the remaining HD patients. Indeed, when compared without these 2 outliers, LDL apoB FCR was found also to be significantly decreased in the HD group (0.306 pools/day) as compared with the control group (0.376 pools/day, $P = 0.0008$) indicating agreement with our results.

Several mechanisms might contribute to our observations. First, the diminished LDL catabolism in HD patients might be explained by a possible contribution of LDL uptake by the healthy human kidney, which does not function appropriately in chronic kidney failure. In fact, glomerular cells like mesangial or epithelial cells have been shown in vitro to express lipoprotein receptors and to take up LDL comparably to fibroblasts and hepatocytes.⁴⁶ It is, however, completely unclear whether the kidney plays a significant role in LDL catabolism in vivo. Perfusion studies in rat kidneys indicated that virtually no intact LDL is cleared from the circulation by the kidney.⁴⁷ Second, the impaired lipolytic cascade in HD patients most likely also contributes to our results. The relatively normal VLDL levels and kinetic parameters and the corresponding impaired IDL parameters are in good accordance with previous findings of normal lipoprotein lipase masses but significantly decreased activities of hepatic triglyceride lipase (HTGL) in HD patients.⁴⁸ Because HTGL promotes the conversion of IDL to LDL, a decrease in HTGL activity might contribute to the accumulation of IDL and reduced PRs of LDL (without accumulating small dense LDL) in HD patients. In fact, analysis of the Japanese subjects of this study showed the conversion rate from IDL to LDL ($k[5,4]$) to be significantly decreased by 68% to 2.87 ± 1.02 pools per day in HD patients as compared with 8.89 ± 4.94 pools per day in control subjects ($P = 0.014$), which is consistent with the previously reported 47% decrease in HTGL activity in HD patients.⁴⁸

Disorders in the metabolism of LDL with normal circulating plasma LDL levels have been reported to result from overproduction and increased clearance of LDL (reviewed by Grundy et al⁴⁹). Several impairments in LDL metabolism, including reduced clearance and increased PRs, have been described in various renal diseases.^{17,18,50} In contrast to the

results shown in this study in HD patients, they all, however, result in elevated LDL plasma levels. Because lipoprotein metabolism substantially differs between the various stages and treatment modalities of chronic kidney disease (reviewed in⁵), it is not surprising to find the respective kinetic parameters of VLDL-, IDL-, LDL-apoB differently reported between predialysis, HD, and peritoneal dialysis.¹⁷⁻¹⁹

The implications of our study are far-reaching and not restricted to the investigated patient group. To the best of our knowledge, this is the first described example of a clinical condition in which reduced synthesis and clearance rates of an atherogenic lipoprotein are masked by normal plasma concentrations. The obtained results therefore demonstrate the need for in vivo kinetic studies to understand complex metabolic systems in humans, even in situations where the snap-shot ex vivo values seem to be almost normal. In particular, the observed alterations in lipoprotein metabolism put HD patients at high risk for developing atherosclerotic disease despite their normal cholesterol and LDL cholesterol plasma levels. These patients should therefore be identified and given appropriate therapy. In fact, recent studies using lipid-lowering therapy of ESRD (including HD) demonstrated a substantial normalization of the dyslipidemic plasma profile and reduced progression of renal disease^{51,52} and in one study also showed reduced mortality⁵³ in these patients. Because most lipid-lowering drugs act by "normalizing" the residential times of the major atherogenic lipoproteins IDL and LDL,⁵⁴ these drugs are expected to correct some of the basic defects of the severely disturbed lipoprotein metabolism in HD patients. Kinetic studies of the impact of lipid-lowering medication on the lipoprotein metabolism of ESRD (including HD) patients are therefore urgently required.

Acknowledgments

This study was supported by the Austrian Science Fund (P10090-MED, P12358-MED), the Fonds zur Förderung an den Universitätskliniken Innsbruck Nr. 52, the Deutsche Forschungsgemeinschaft (DFG - Scha 410/3-1), the Austrian National Bank (9331), and the Austrian Heart Fund. We thank Gerd Utermann for helpful discussions and critical reading of the manuscript and Tomohiro Wakikawa, Sabine Motzny, Alexander Sattler, Alexander Starke, Muhidien Soufi, and Linda Fineder for their excellent technical support.

References

- Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. *N Engl J Med*. 1974;290:697-701.
- Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis*. 1998;32:S112-S119.
- Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. *Lancet*. 2000;356:147-152.
- Kronenberg F. Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease. *Curr Opin Nephrol Hypertens*. 1998;7:271-278.
- Kronenberg F. Lipoprotein abnormalities in end-stage renal failure. In: Loscalzo J, London GM, eds. *Cardiovascular disease in end-stage renal failure*. Oxford, UK: Oxford University Press; 2000:175-206.
- Bagdade JD, Porte D Jr, Bierman EL. Hypertriglyceridemia. A metabolic consequence of chronic renal failure. *N Engl J Med*. 1968;279:181-185.
- Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. *Kidney Int*. 1981;19:625-637.
- Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. *Am J Kidney Dis*. 2001;38:S30-S33.
- Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. *Am J Kidney Dis*. 1996;27:1-25.
- Fuh MMT, Lee C-M, Jeng C-Y, Shen D-C, Shieh S-M, Reaven GM, Chen Y-DI. Effect of chronic renal failure on high-density lipoprotein kinetics. *Kidney Int*. 1990;37:1295-1300.
- Dieplinger H, Schoenfeld PY, Fielding CJ. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. *J Clin Invest*. 1986;77:1071-1083.
- Kronenberg F, König P, Neyser U, Auinger M, Pribasnig A, Lang U, Reitingner J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol*. 1995;6:110-120.
- O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. *Am J Kidney Dis*. 1996;27:84-91.
- Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. *J Clin Endocrinol Metab*. 2003;88:4525-4532.
- Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. *Kidney Int*. 1984;25:812-818.
- Chan PC, Persaud J, Varghese Z, Kingstone D, Baillood RA, Moorhead JF. Apolipoprotein B turnover in dialysis patients: its relationship to pathogenesis of hyperlipidemia. *Clin Nephrol*. 1989;31:88-95.
- Hörkkö S, Huttunen K, Kesäniemi YA. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. *Kidney Int*. 1995;47:1732-1740.
- Hörkkö S, Huttunen K, Korhonen T, Kesäniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. *Kidney Int*. 1994;45:561-570.
- Prinsens BH, Rabelink TJ, Romijn JA, Bisschop PH, de Barse MM, de Boer J, van Haften TW, Barrett PH, Berger R, de Sain-van der Velden MG. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. *Kidney Int*. 2004;65:1064-1075.
- Schaefer JR, Rader DJ, Brewer B. Investigation of lipoprotein kinetics using endogenous labeling with stable isotopes. *Curr Opin Lipidol*. 1992;3:227-232.
- Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, Winkler K, Steinmetz A, Marz W. Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. *Arterioscler Thromb Vasc Biol*. 1997;17:348-353.
- Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. *J Lipid Res*. 1993;34:2207-2215.
- Schweer H, Watzler B, Seyberth HW, Steinmetz A, Schaefer JR. Determination of isotopic ratios of L-leucine and L-phenylalanine and their stable isotope labeled analogues in biological samples by gas chromatography/triple-stage quadrupole mass spectrometry. *J Mass Spectrom*. 1996;31:727-734.
- Cobelli C, Toffolo G, Foster DM. Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. *Am J Physiol*. 1992;262:E968-E975.
- Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. *Metabolism*. 1998;47:484-492.
- Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech LA, Nagano M, Nakamura H, Brewer HB Jr, Rader DJ. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. *J Clin Invest*. 1995;96:1573-1581.
- Kronenberg F, Trenkwalder E, Kronenberg MF, König P, Utermann G, Dieplinger H. Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a). *Kidney Int*. 1998;54:1385-1389.
- Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales L, Levin NW. Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. *Kidney Int*. 2003;63:315-322.

29. Giordano M, De Feo P, Lucidi P, dePascale E, Giordano G, Infantone L, Zoccolo AM, Castellino P. Increased albumin and fibrinogen synthesis in hemodialysis patients with normal nutritional status. *J Am Soc Nephrol*. 2001;12:349–354.
30. Mitra S, Chamney P, Greenwood R, Farrington K. Serial determinations of absolute plasma volume with indocyanine green during hemodialysis. *J Am Soc Nephrol*. 2003;14:2345–2351.
31. Weidmann P, Beretta-Piccoli C, Steffen F, Blumberg A, Reubi FC. Hypertension in terminal renal failure. *Kidney Int*. 1976;9:294–301.
32. Katzarski KS, Nisell J, Randmaa I, Danielsson A, Freyschuss U, Bergstrom J. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. *Am J Kidney Dis*. 1997;30:459–465.
33. Greger R, Windhorst U. Comprehensive human physiology. From cellular mechanisms to integration. Berlin-Heidelberg: Springer Verlag; 1996.
34. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). *J Clin Invest*. 1993;91:397–401.
35. Demant T, Packard CJ, Demmelmair H, Stewart P, Bedynek A, Bedford D, Seidel D, Shepherd J. Sensitive methods to study human apolipoprotein B metabolism using stable isotope-labeled amino acids. *Am J Physiol*. 1996;270:E1022–E1036.
36. Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. *J Lipid Res*. 2000;41:305–318.
37. Schultze G, Piefke S, Molzahn M. Blood pressure in terminal renal failure. Fluid spaces and the renin-angiotensin-system. *Nephron*. 1980; 25:15–24.
38. Andrulli S, Colzani S, Mascia F, Lucchi L, Stipo L, Bigi MC, Crepaldi M, Redaelli B, Albertazzi A, Locatelli F. The role of blood volume reduction in the genesis of intradialytic hypotension. *Am J Kidney Dis*. 2002;40: 1244–1254.
39. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. *Kidney Int*. 2005;68:766–772.
40. Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. *Arterioscler Thromb Vasc Biol*. 2000;20:E63–E67.
41. Boaz M, Smetana S, Weinstein T, Matas Z, Gafer U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. *Lancet*. 2000;356: 1213–1218.
42. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. *Circulation*. 2003;107: 992–995.
43. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. *J Am Soc Nephrol*. 1998;9:1277–1284.
44. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. *J Clin Invest*. 1991;87:591–596.
45. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men. *J Lipid Res*. 1995;36:1155–1167.
46. Quaschnig T, Koniger M, Kramer-Guth A, Greiber S, Pavenstadt H, Nauck M, Schollmeyer P, Wanner C. Receptor-mediated lipoprotein uptake by human glomerular cells: comparison with skin fibroblasts and HepG2 cells. *Nephrol Dial Transplant*. 1997;12:2528–2536.
47. Pegoraro AA, Gudehithlu KP, Cabrera E, Shankar R, Arruda JA, Dunea G, Singh AK. Handling of low-density lipoprotein by the renal tubule: release of fragments due to incomplete degradation. *J Lab Clin Med*. 2002;139:372–378.
48. Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. *Kidney Int Suppl*. 1999; 71:S227–S228.
49. Grundy SM, Vega GL, Kesaniemi YA. Abnormalities in metabolism of low density lipoproteins associated with coronary heart disease. *Acta Med Scand Suppl*. 1985;701:23–37.
50. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, Rabelink TJ. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. *Kidney Int*. 1998;53:994–1001.
51. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. *Kidney Int*. 2001;59: 260–269.
52. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. *Kidney Int Suppl*. 1999;71:S134–S136.
53. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. *Kidney Int*. 2002;61:297–304.
54. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. *J Intern Med*. 1991; 230:341–350.



Effects of diacylglycerol ingestion on postprandial hyperlipidemia in diabetes

Norio Tada^{a,*}, Kentaro Shoji^b, Masao Takeshita^b, Hiroyuki Watanabe^{b,1},
Hiroshi Yoshida^a, Tadashi Hase^b, Noboru Matsuo^b, Ichiro Tokimitsu^b

^aDepartment of Internal Medicine, Division of General Medicine, Kashiwa Hospital, The Jikei University School of Medicine,
163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan

^bHealth Care Products Research Laboratories, Kao Corporation, 2-1-3, Bunka Sumida-ku Tokyo 131-8501, Japan

Received 10 February 2004; received in revised form 12 October 2004; accepted 12 October 2004

Abstract

Background: We previously reported that diacylglycerol (DAG) as compared with triacylglycerol (TAG) suppressed increases in postprandial lipids in healthy volunteers. This study was to investigate the effects of DAG on postprandial lipids, particularly remnant lipoproteins in diabetics.

Methods: Emulsified DAG oil or TAG oil with a fatty acid composition similar to DAG oil was orally administered (30 g fat/m² of body surface) to moderately controlled six diabetics, with hemoglobin A1c (HbA1c) below 8%, after fasting for at least 12 h in a randomized crossover manner. Serum cholesterol and TAG, lipids in remnant-like particles (RLP), and other lipid parameters including serum ketone bodies were measured prior to and 2, 4, and 6 h after fat loading.

Results: DAG loading significantly suppressed increases in postprandial serum TAG and lipids in RLP as compared with TAG loading. The incremental area under the curve (IAUC) for serum TAG and that for lipids in RLP with DAG loading were also significantly smaller than those with TAG loading. However, changes in serum levels of insulin, free fatty acids, and ketone bodies during fat loading were essentially the same for DAG and TAG.

Conclusions: This pilot study suggests that substituting DAG intake for TAG may be beneficial to moderately controlled diabetics due to its effect in reducing postprandial hyperlipidemia.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Diacylglycerol; Remnant lipoprotein; Remnant-like particles; Postprandial hyperlipidemia; Diabetes

* Corresponding author. Tel.: +81 4 7164 1111x3260; fax: +81 4 7164 1126.

E-mail address: n-tada27@jikei.ac.jp (N. Tada).

¹ Current address: Department of Food and Nutrition, Toita Woman's College, 2-21-17 Shiba, Minato-ku, Tokyo, 105-0014 Japan.

1. Introduction

A greatly enhanced risk for coronary heart disease (CHD) has been reported in diabetes [1,2]. Lipid abnormalities in diabetes, including elevated plasma tri-

acylglycerol (TAG), low cholesterol in high-density lipoproteins (HDL), an increase in small, dense low-density lipoproteins (LDL), and postprandial hyperlipidemia contribute to this increased risk [3–6]. Among them, postprandial increase in remnant lipoproteins (remnants) has been recognized as a powerful CHD risk not only for diabetic but also for nondiabetic subjects [7–12].

Remnants are the metabolites of TAG-rich lipoproteins, such as chylomicrons (CM) and very-low-density lipoproteins (VLDL), and are formed in the circulation by the effect of lipoprotein lipase. These remnants are readily incorporated into endothelial macrophages, leading to the accumulation of cholesterol in these cells, consequently forming a premature atherosclerotic lesion [9,12–14].

Therapeutic approaches to reduce remnant levels in the postprandial phase are believed to be important for the management of patients with diabetes and also with metabolic syndrome [5]. We have previously reported [15] that the substitution of diacylglycerol (DAG) oil intake for TAG oil significantly suppressed postprandial increases in serum TAG and lipids in remnants measured by the method of Nakajima et al. [16] in healthy male volunteers. Therefore, we had an interest whether this favorable effect of DAG intake on postprandial hyperlipidemia can be applied to diabetic subjects without any serious adverse phenomenon.

Diacylglycerol is a natural component of various edible oils and consists mainly of the 1,3-species. The intake of DAG has been reported to reduce fasting serum TAG concentration and hemoglobin A1c (HbA1c) levels in type 2 diabetics and to

prevent the accumulation of body fat in experimental animals and in humans [17,18]. Decreased activities of enzymes of fatty acid synthesis and increased activities of enzymes involved in the β -oxidation pathway by DAG ingestion have also been reported [18].

The objectives of this study were to investigate the effects of oral DAG loading on postprandial changes in serum lipids, related parameters including ketone bodies, and changes in remnants in moderately controlled diabetics.

2. Materials and methods

2.1. Subjects

The subjects were six patients with type 2 diabetes mellitus (five females and one male; aged 46–70 years) who had moderately controlled HbA1c levels that were <8%. The study was performed in accordance with the principle of the Helsinki Declaration. The subjects were fully informed concerning the study and gave their informed consent. The clinical characteristics of subjects are shown in Table 1. All of them were not receiving insulin therapy, but they were medicated as follows: one was taking both a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and a hypotensive drug; five subjects were taking oral antidiabetic drugs (sulfonylurea, biguanides, and α -glucosidase inhibitors), and two of these five were also taking HMG-CoA reductase inhibitors, and the others were taking hypotensive drugs concomitantly.

Table 1
Characteristics of subjects

No.	Age (years)	Height (m)	Weight (kg)	FPG (mmol/l)	HbA1c (%)	Serum TAG (mmol/l)	Serum T-Chol (mmol/l)	HDL-C (mmol/l)
1	59	1.47	59	7.3	6.5	1.75	4.85	2.12
2	46	1.50	65	7.5	7.8	0.89	5.35	1.27
3	70	1.48	54	6.1	6.5	0.69	5.53	1.32
4	67	1.64	57	11.5	7.6	1.34	5.06	1.11
5	59	1.47	47	9.3	7.6	0.88	5.47	2.24
6	68	1.57	56	9.6	6.8	0.59	5.64	1.86
Mean \pm S.E.	62 \pm 4	1.52 \pm 0.03	56 \pm 2	8.6 \pm 0.8	7.1 \pm 0.2	1.03 \pm 0.18	5.32 \pm 0.12	1.65 \pm 0.20

TAG: triacylglycerol; BMI: body mass index; FPG: fasting plasma glucose; T-Chol: total cholesterol.

2.2. Experimental oils

The DAG oil was prepared by esterifying glycerol with fatty acids from soybean and rapeseed oil according to the method of Huge-Jensen et al. [19]. The product contained 1,3-DAG and 1,2-DAG isomers in a ratio of 7:3 with a total DAG content of approximately $\geq 80\%$. Triacylglycerol oil was prepared by mixing rapeseed, safflower, and perilla oils to give a final fatty acid composition that was similar to that of the DAG oil. The fatty acid compositions of the DAG and TAG oils are shown in Table 2. No appreciable differences in combustion energy were detected between the DAG and TAG oils [20].

2.3. Study design

The study was designed in a double-blind cross-over style with a 2-week interval. The medications were not changed during the period of interval. The protocol was substantially the same as that as previously reported [15]. Briefly, the patients ingested emulsified test oil (TAG or DAG oil) at a dose of 30 g fat/m² of body surface area in the morning after fasting for approximately 12 h. The test oil emulsions contained 35% oil, 1% casein sodium, 3% skim milk, 0.5% fatty acid sucrose polyester, 0.36% soybean lecithin, and 60.14% water. During the study, patients were asked to remain seated with minimum physical activity. Patients were also requested not to take any drugs or food except for water from the morning of the test day to the final blood sample collection.

Blood samples were collected before fat loading for baseline measurements (initial value) and at 2, 4, and 6 h after fat loading. Two weeks later, the same

patients received the opposite test oil, and blood samples were collected at the same time points.

2.4. Sample analysis

Serum lipids, lipids in lipoproteins, HDL-cholesterol (HDL-C), and serum apolipoprotein concentrations were measured as described elsewhere [15]. The concentrations of serum total ketone bodies [21] and plasma glucose [22] were measured by enzymatic methods. Serum insulin [23] and plasma plasminogen-activator inhibitor 1 (PAI-1) [24] were measured by enzyme immunoassay methods. Plasma preheparin lipoprotein lipase (LPL) protein mass was measured by the method of Kobayashi et al. [25]. Serum leptin was measured by radioimmunoassay [26]. The remnant-like particle (RLP) fraction was isolated from the serum of each sample by means of an immunoaffinity-mixed gel conjugated with anti-apoB-100 and anti-apoAI monoclonal antibodies [16].

Lipoprotein fractions were obtained from the serum sample by sequential preparative ultracentrifugation [27] using a Hitachi RP65T rotor. Chylomicrons (Svedberg floatation >400 lipoproteins) were isolated at 20,000 rpm for 30 min at 15 °C, and very-low-density lipoproteins (VLDL; $d < 1.006$ g/ml) were isolated further at 40,000 rpm for 16 h at 4 °C. Then, serum density was adjusted by adding potassium bromide. LDL ($1.006 < d < 1.063$ g/ml) and HDL ($1.063 < d < 1.21$ g/ml) fractions were isolated sequentially at 40,000 rpm for 20 and 40 h, respectively, at 4 °C. Separated LDL and HDL were dialyzed against 0.15 mol/l NaCl. TAG concentrations of the isolated lipoprotein fractions were determined by enzymatic methods.

2.5. Statistical analysis

Measured values and changes (Δ) from the initial values are presented as mean \pm standard error (S.E.). Statistical analyses were performed using SPSS (version 11.0: SPSS, Chicago IL). Differences between the groups in the time course changes from the initial values were analyzed using repeated-measures two-way ANOVA. The difference between the measured values during DAG and TAG loading test at each time point was assessed by a paired *t*-test. The incremental area under the curve (IAUC) of blood variables during 6 h after fat loading was calculated,

Table 2
Fatty acid composition of test oils (wt.%)

	DAG	TAG
C16	3.1	5.4
C18	1.1	2.1
C18:1	38.3	34.3
C18:2	47.7	49.2
C18:3	9.0	7.8
C20	0.3	0.5
C20:1	0.2	0.3

DAG: diacylglycerol; TAG: triacylglycerol.

Table 3
Changes in serum concentrations of lipids

		Time after fat loading (h)				<i>p</i> value of ANOVA
		0	2	4	6	
T-Chol (mmol/l)	DAG	5.25±0.16 (0.00)	5.35±0.13 (0.08±0.08)	5.22±0.10 (-0.05±0.08)	5.28±0.13 (0.03±0.08)	<i>p</i> =0.330
	TAG	5.38±0.16 (0.00)	5.35±0.13 (-0.03±0.05)	5.33±0.13 (-0.05±0.05)	5.28±0.13 (-0.10±0.05)	
LDL-C (mmol/l)	DAG	3.28±0.23 (0.00)	3.34±0.26 (0.08±0.08)	3.23±0.23 (-0.05±0.05)	3.18±0.23 (-0.10±0.08)	<i>p</i> =0.617
	TAG	3.26±0.28 (0.00)	3.26±0.26 (0.00±0.05)	3.18±0.26 (-0.08±0.05)	3.18±0.28 (-0.08±0.05)	
HDL-C (mmol/l)	DAG	1.66±0.21 (0.00)	1.63±0.18 (-0.03±0.03)	1.60±0.18 (-0.08±0.05)	1.63±0.21 (0.00±0.03)	<i>p</i> =0.567
	TAG	1.63±0.18 (0.00)	1.66±0.18 (0.00±0.05)	1.58±0.18 (-0.08±0.03)	1.60±0.18 (-0.05±0.00)	
TAG (mmol/l)	DAG	0.94±0.19 (0.00)	1.46±0.33 (0.52±0.23)	1.59±0.42 (0.64±0.23)	1.41±0.26 (0.14±0.11)	<i>p</i> =0.005
	TAG	1.11±0.20 (0.00)	1.77±0.32 (0.68±0.27)	1.80±0.34 (0.69±0.18)	1.41±0.36 (0.32±0.17)	
FFA (mmol/l)	DAG	0.51±0.06 (0.00)	0.63±0.07 (0.11±0.04)	0.87±0.09 (0.36±0.07)	0.82±0.11 (0.31±0.09)	<i>p</i> =0.567
	TAG	0.59±0.08 (0.00)	0.75±0.11 (0.16±0.16)	0.79±0.06 (0.21±0.11)	0.85±0.13 (0.27±0.13)	
RLP-C (mmol/l)	DAG	0.11±0.01 (0.00)	0.17±0.03 (0.06±0.03)	0.17±0.04 (0.06±0.02)	0.13±0.02 (0.03±0.01)	<i>p</i> =0.021
	TAG	0.11±0.02 (0.00)	0.21±0.02 (0.10±0.02)	0.20±0.03 (0.09±0.02)	0.15±0.03 (0.05±0.02)	
RLP-TAG (mmol/l)	DAG	0.14±0.04 (0.00)	0.48±0.15 (0.34±0.14)	0.52±0.19 (0.38±0.14)	0.29±0.08 (0.15±0.05)	<i>p</i> =0.004
	TAG	0.15±0.04 (0.00)	0.67±0.19 (0.52±0.18)	0.59±0.13 (0.44±0.10)	0.41±0.13 (0.26±0.09)	

Values are Mean±S.E. Mean±S.E. changes from baseline are shown in parentheses (Δ). *Significantly different from TAG ingestion at the same time points by paired *t*-test: *p*<0.05. *P* values are calculated by repeated-measures two-way ANOVA (Δ). DAG: diacylglycerol; TAG: triacylglycerol; T-Chol: total cholesterol; FFA: free fatty acids.

and the differences between the treatment groups were assessed by a paired *t*-test. *P* values <0.05 were considered to be significant for all analyses.

3. Results

3.1. Changes in serum lipids and apolipoproteins

Table 3 shows changes in serum lipids, LDL-C, HDL-C, and RLP lipids. Serum total cholesterol, LDL-C, and HDL-C did not change during TAG or DAG loading. However, serum TAG increased, peaking at 4 h after the loading with either oil and

decreased at 6 h. Increases (Δ: shown in the parentheses in Table 3) in serum TAG from the initial value were significantly smaller during DAG loading than those observed during TAG loading (*p*=0.005), as determined by two-way ANOVA. No significant difference in serum TAG levels after fat loading was observed between the TAG and DAG study groups at any time point. Serum FFA was increased during TAG or DAG loading, and changes in these values were not different significantly between the two study groups.

The RLP lipids, RLP-C and RLP-TAG, were increased, peaking at 2 or 4 h and then decreased toward the initial value as a function of time after the loading of either oil. However, increases in RLP-C

Table 4
Changes TAG in CM, VLDL, LDL, and HDL

		Time after fat loading (h)				<i>p</i> value of ANOVA
		0	2	4	6	
CM (mmol/l)	DAG	0.01±0.01 (0.00)	0.27±0.13 (0.25±0.13)	0.30±0.12 (0.29±0.12)	0.12±0.05 (0.10±0.04)	<i>p</i> =0.141
	TAG	0.02±0.01 (0.00)	0.37±0.16 (0.35±0.16)	0.31±0.06 (0.30±0.05)	0.17±0.07 (0.15±0.07)	
VLDL (mmol/l)	DAG	0.38±0.16 (0.00)	0.55±0.18 (0.17±0.06)	0.59±0.22 (0.20±0.06)	0.36±0.16 (-0.02±0.05)	<i>p</i> =0.796
	TAG	0.52±0.16 (0.00)	0.70±0.17 (0.17±0.07)	0.72±0.22 (0.20±0.09)	0.53±0.21 (0.01±0.07)	
LDL (mmol/l)	DAG	0.34±0.04 (0.00)	0.33±0.04 (0.00±0.01)	0.33±0.04 (0.00±0.01)	0.32±0.05 (-0.01±0.02)	<i>p</i> =0.097
	TAG	0.34±0.04 (0.00)	0.34±0.04 (0.00±0.00)	0.35±0.04 (0.00±0.00)	0.35±0.04 (0.01±0.01)	
HDL (mmol/l)	DAG	0.14±0.02 (0.00)	0.16±0.02 (0.02±0.01)	0.18±0.03 (0.04±0.02)	0.16±0.03 (0.01±0.01)	<i>p</i> =0.585
	TAG	0.17±0.01 (0.00)	0.19±0.01 (0.02±0.01)	0.21±0.02 (0.03±0.02)	0.18±0.02 (0.01±0.01)	

Values are Mean±S.E. Mean±S.E. changes from baseline are shown in parentheses (Δ). *P* values are calculated by repeated-measures two-way ANOVA (Δ). DAG: diacylglycerol; TAG: triacylglycerol.




Fig. 1. Incremental area under the curve (IAUC) for serum TAG with either TAG or DAG loading ($n=6$). Increases in serum TAG were monitored during 6 h after a single loading of either TAG or DAG orally. This figure shows the difference of individual IAUC for serum TAG between TAG and DAG loading, and IAUC for serum TAG in the DAG group were significantly lower when compared with those in the TAG group ($p<0.05$). DAG: diacylglycerol; TAG: triacylglycerol.

and RLP-TAG from the initial values (Δ) after DAG loading were significantly smaller than those after TAG loading.

Changes in TAG level in each lipoprotein, separated by ultracentrifugation, with fat loading are shown in Table 4. No significant differences in terms of changes in these values were found between the TAG and DAG groups. However, the duration to the peak CM-TAG after fat loading was longer in the case of DAG loading compared with that in the TAG loading group, suggesting a slower production of CM during the DAG loading, although the difference

between the groups was not significant. Apolipoproteins AI, AII, B, CII, CIII, and E were decreased during either fat loading, and changes in these parameters were not significantly different between TAG and DAG loading (data not shown).

3.2. Incremental area under the curve (IAUC) of serum TAG and RLP lipids

Differences of IAUC for serum TAG and RLP lipids between DAG and TAG ingestion, monitored up to 6 h after the loading with test oil, are shown in Figs. 1 and 2, respectively. The mean values of IAUC for serum TAG, RLP-C, and RLP-TAG in the DAG group were all significantly lower when compared with those in the TAG group ($p<0.05$).

3.3. Changes in serum insulin, plasma glucose, serum total ketone bodies, plasma LPL protein mass, serum leptin, and plasma PAI-1

As listed in Table 5, serum insulin was increased slightly at 2 h and then decreased at 4 and 6 h after either of the fat loading, and there were no significant differences between the values for TAG and DAG loading. Plasma glucose was gradually decreased with time after either of the fat loading. Decreases in plasma glucose from the initial value (Δ) at 2 and 4 h were significantly larger with TAG loading than those with DAG loading. Overall, decreases in plasma glucose during TAG loading were significantly greater




Fig. 2. Incremental area under the curve (IAUC) for RLP lipids with either TAG or DAG loading ($n=6$). Increases in RLP-TAG (a) and RLP-C (b) were monitored during 6 h after a single loading of either TAG or DAG orally. This figure shows the difference of individual IAUC for RLP-TAG (a) and RLP-C (b) between TAG and DAG loading. IAUC for both RLP-TAG (a) and RLP-C (b) in the DAG group were significantly lower when compared with those in the TAG group, respectively (each $p<0.05$). DAG: diacylglycerol; TAG: triacylglycerol; RLP: remnant-like particles.

Table 5
Changes in concentrations of serum insulin, plasma glucose, serum leptin, plasma LPL protein mass, plasma PAI-1

		Time after fat loading (h)				<i>p</i> value of ANOVA
		0	2	4	6	
Insulin (pmol/l)	DAG	45.0±13.2 (0.0)	46.8±6.6 (1.8±9.0)	36.0±7.8 (−9.0±9.0)	25.2±4.8 (−19.8±11.4)	<i>p</i> =0.936
	TAG	47.4±9.0 (0.0)	54.6±11.4 (7.2±6.0)	33.0±4.8 (−14.4±7.2)	31.2±9.6 (−16.2±7.8)	
Glucose (mmol/l)	DAG	8.3±0.9 (0.0)	7.8±0.8 (−0.4±0.3)*	6.8±0.8 (−1.5±0.3)*	6.1±0.6 (−2.2±0.4)	<i>p</i> =0.037
	TAG	8.8±0.8 (0.0)	7.5±0.7 (−1.3±0.2)	6.2±0.5 (−2.6±0.3)	5.9±0.4 (−2.9±0.6)	
Leptin (μg/l)	DAG	7.7±2.0 (0.0)	6.8±1.8 (−0.9±0.3)	6.4±1.8 (−1.4±0.3)	6.3±1.7 (−1.4±0.5)	<i>p</i> =0.741
	TAG	7.3±1.8 (0.0)	6.5±1.6 (−0.8±0.2)	5.9±1.4 (−1.4±0.4)	6.1±1.5 (−1.3±0.4)	
Preheparin LPL protein mass (g/l)	DAG	0.52±0.07 (0.00)	0.48±0.05 (−0.04±0.04)	0.45±0.05 (−0.07±0.04)	0.40±0.04 (−0.11±0.05)	<i>p</i> =0.460
	TAG	0.54±0.09 (0.00)	0.51±0.07 (−0.03±0.03)	0.49±0.07 (−0.06±0.03)	0.48±0.07 (−0.06±0.02)	
PAI-1 (μg/l)	DAG	17±3 (0)	16±3 (−1±4)	14±3 (−3±4)	9±1 (−8±3)	<i>p</i> =0.554
	TAG	15±3 (0)	17±3 (2±2)	14±2 (−1±2)	11±2 (−5±2)	
T-ketone bodies (μmol/l)	DAG	153±63 (0)	145±31 (−8±53)	443±74 (290±67)	506±108 (353±113)	<i>p</i> =0.074
	TAG	127±43 (0)	230±53 (102±69)	443±111 (315±118)	507±118 (380±112)	

Values are Mean±S.E. Mean±S.E. changes from baseline are shown in parentheses (Δ). *P* values are calculated by repeated-measures two-way ANOVA (Δ). DAG: diacylglycerol; TAG: triacylglycerol; LPL: lipoprotein lipase; T-ketone bodies: total ketone bodies.

* Significantly different from TAG ingestion at the same time points by paired *t*-test: *p*<0.05.

in comparison with those during DAG loading (*p*<0.05). The concentration of total ketone bodies in the serum was increased over time following either fat loading, but no significant difference was observed between the values for TAG and DAG loading. Plasma LPL protein mass, serum leptin, and plasma PAI-1 decreased over time after either fat loading, and there were no significant differences between these respective values in the TAG and DAG groups.

4. Discussion

The effects of DAG loading on postprandial changes in serum lipids and lipid parameters in diabetic patients were examined. Although the subject number of this study was small, the findings again showed the suppressed postprandial increases in serum TAG, RLP-TAG, and RLP-C in the DAG intake when compared with TAG intake in diabetic subjects as previously reported in healthy volunteers [15].

Increased fasting RLP-C concentrations have been reported in individuals with impaired glucose tolerance and in subjects with type 2 diabetes [1]. Ai et al. [28] reported that postprandial TAG and lipids in the RLP were also significantly increased in type 2 diabetics as compared with those in healthy subjects. In a recent report from the Framingham Study, RLP-C

and RLP-TAG levels were shown to be higher in diabetic males and females, and these increases in RLP lipids were counted as a risk factor for CHD [29]. In the subanalysis of the Veterans Affairs HDL Intervention Trial (VA-HIT), a randomized controlled trial, Elam et al. [30] also reported that the incidence of CHD events was correlated positively to preprandial RLP-TAG and RLP-C levels. Furthermore, Mero et al. [31] suggested that postprandial changes in small remnant number might contribute to the severity of CAD in type 2 diabetes. These data suggest that the suppression of the postprandial increase in RLP lipids, achieved in our preliminary study by DAG loading, may be helpful to construct a nutritional therapeutic strategy, for reducing CHD risk, in diabetic patients.

The physicochemical mechanisms of the DAG oil-induced suppression of the postprandial increase in lipids have not yet been fully elucidated. During the processes of digestion, dietary TAG molecules are hydrolyzed to yield two free fatty acids and 2-monoacylglycerol (2-MAG) by intestinal lipases and absorbed into enterocytes. Triacylglycerol is then reassimilated again mainly via 2-MAG pathway in enterocytes [32]. On the other hand, 1,3-DAG, a major constituent of DAG, is hydrolyzed to glycerol and free fatty acids through 1-(or 3-)MAG during digestion. A portion of the 1-(or 3-)MAG enters enterocytes in the same manner as 2-MAG. However, resynthesis of TAG from 1-(or 3-)MAG will take

palace via the phosphatidic acid pathway, a slow turnover pathway, instead of the 2-MAG pathway. Hence, the lymphatic secretion of CM-TAG after the ingestion of DAG oil might be slower and possibly lower than that after the ingestion of naturally occurring TAG oil. These properties of 1,3-DAG may be beneficial in improving postprandial hyperlipidemia. Other metabolic characteristics of 1,3-DAG were discussed elsewhere recently [33].

As shown in Table 4, the increase in CM-TAG with DAG loading was slightly lower, and the time required for CM-TAG to reach the maximum level following DAG loading was longer as compared with TAG loading, although significant differences between the two groups were not detected. Eventually, however, these phenomena may lead to the significant suppression of the postprandial increase in serum TAG and RLP lipids after DAG loading.

Another aim of this experiment was to investigate the adverse effects of DAG intake especially on the formation of ketone bodies in diabetes. It is known that most diabetic patients have an abnormal ketone body metabolism. It was reported that higher activities of enzymes involved in the beta-oxidation pathway were detected with DAG feeding as compared with TAG feeding in the rat liver [34]. Increased fat oxidation was also detected in an experiment with 12 women who ingested DAG as compared with TAG oil [35]. Retarded TAG resynthesis in the enterocyte with DAG feeding, as described above, can result in an increased fatty acid concentration in enterocytes. Fatty acids unutilized for de novo TAG resynthesis in enterocytes may be utilized as energy. The retarded glucose reduction observed in our study during DAG loading as compared with TAG loading (Table 5) is conceivably due to the utilization of fatty acids instead of glucose as an energy source. This retarded glucose reduction during the DAG loading was also reported in healthy subjects by Taguchi et al. [36]. Thus, an increase in ketone bodies in the circulation following oral DAG loading in diabetics was our concern. However, this study showed no significant difference in the concentration of serum ketone bodies between the TAG and DAG groups for the moderately controlled diabetic patients with HbA_{1c} levels <8%. Although we evaluated postprandial responses of single loading of DAG oil by

the comparison with TAG oil using fat emulsion as a test food, oils in a typical diet should be evaluated as the next step with much larger population of diabetic subjects.

In summary, DAG ingestion in contrast to TAG ingestion suppressed postprandial increases in serum TAG, RLP-C, and RLP-TAG in six diabetics with moderate glycemic control. In addition, no significant differences were observed in postprandial changes in serum levels of insulin, free fatty acid, and ketone bodies between the DAG and TAG loading.

Acknowledgement

A part of this study was supported by Health and Labor Sciences Research Grants for Comprehensive Research on Aging and Health (H15-Choju-012), Japan.

References

- [1] Bierman EL. Atherogenesis in diabetes. *Arterioscler Thromb* 1992;12:647–56.
- [2] Haffner SM, Lehto S, Ronemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–34.
- [3] Laakso M. Hyperlipidemia and cardiovascular disease in type 2 diabetes. *Diabetes* 1999;48:937–42.
- [4] Evans M, Khan N, Rees A. Diabetic dyslipidemia and coronary heart disease: new perspectives. *Curr Opin Lipidol* 1999;10:387–91.
- [5] Cottrell DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. *Curr Opin Cardiol* 2003;18:301–8.
- [6] Ginsberg HN. Treatment for patients with the metabolic syndrome. *Am J Cardiol* 2003;91:29E–39E [suppl].
- [7] Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay A, Bouchard C, et al. Postprandial triglyceride response in visceral obesity in men. *Diabetes* 1998;47:953–60.
- [8] Zilverman DB. Atherogenesis: a postprandial phenomenon. *Circulation* 1979;60:473–85.
- [9] Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. *Curr Opin Lipidol* 1994;5:102–9.
- [10] Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. *J Intern Med* 1999;246:341–55.
- [11] Kugiyama K, Doi H, Takazoe K, Kawano H, Soejima H, Mizuno Y, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. *Circulation* 1999;99:2858–60.
- [12] Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness

- of the carotid artery independently of LDL cholesterol and plasma triglycerides. *J Lipid Res* 2001;42:17–21.
- [13] Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. *Atherosclerosis* 1987;65:181–9.
- [14] Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, Ramshorst E, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. *Arterioscler Thromb* 1991;11:653–62.
- [15] Tada N, Watanabe H, Matsuo N, Tokimitsu I, Okazaki M. Dynamics of postprandial remnant-like lipoprotein particles in serum after loading of diacylglycerols. *Clin Chim Acta* 2001;311:109–17.
- [16] Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. A new assay method for the quantification of cholesterol in remnant like lipoproteins in human serum using monoclonal anti apo B100 and apo A-I immunofluorescence mixed gels. *Clin Chim Acta* 1993;223:53–71.
- [17] Yamamoto K, Asakawa H, Tokunaga K, Watanabe H, Matsuo N, Tokimitsu I, et al. Long-term ingestion of dietary diacylglycerol lowers serum triacylglycerol in type II diabetic patients with hypertriglyceridemia. *J Nutr* 2001;131:3204–7.
- [18] Tada N, Yoshida H. Diacylglycerol on lipid metabolism. *Curr Opin Lipidol* 2003;14:29–33.
- [19] Høge-Jensen B, Galluzzo DR, Jensen RG. Studies on free and immobilized lipases from *Mucor miehei*. *J Am Oil Chem Sci* 1988;65:905–10.
- [20] Taguchi H, Nagao T, Watanabe H, Onizawa K, Matsuo N, Tokimitsu I, et al. Energy value and digestibility of dietary oil containing mainly 1,3-diacylglycerol are similar to those of triacylglycerol. *Lipids* 2001;36:379–82.
- [21] Williamson DH, Mellanby J, Krebs HA. Enzymic determination of D(–)-beta-hydroxybutyric acid and acetoacetic acid in blood. *Biochem J* 1962;82:90–6.
- [22] Slein MW. Determination with hexokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer HU, editor. *Methods of enzymatic analysis*. New York: Academic Press; 1963. p. 117–23.
- [23] Hales CN, Randle PJ. Immunoassay of insulin with insulin antibody precipitate. *Biochem J* 1963;88:137–46.
- [24] Declercq PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. *Blood* 1988;71:220–5.
- [25] Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. *Clin Chim Acta* 1993;216:113–23.
- [26] Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. Radioimmunoassay of leptin in human plasma. *Clin Chem* 1996;42:942–6.
- [27] Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. *Adv Lipid Res* 1968;6:1–68.
- [28] Ai M, Tanaka A, Ogita K, Sekinc M, Numano F, Numano F, et al. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. *J Am Coll Cardiol* 2001;38:1628–32.
- [29] Schaefer EJ, McNamara JR, Shah PK, Nakajima K, Cupples LA, Ordovas JM, et al. Framingham Offspring Study. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. *Diabetes Care* 2002;25:989–94.
- [30] Elam MB, Schaefer EJ, McNamara JR. Fasting and postprandial remnant-like particles (RLP) as predictors of cardiovascular events in the VA-HDL Intervention Trial (VA-HIT). *Circulation* 1999;100:1-470 [abstract].
- [31] Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. *Atherosclerosis* 2000;150:167–77.
- [32] Yang L-Y, Kuksis A. Apparent convergence (at 2-monoacylglycerol level) of phosphatidic acid and 2-monoacylglycerol pathways of synthesis of chylomicron triacylglycerols. *J Lipid Res* 1991;32:1173–86.
- [33] Tada N. Physiological actions of diacylglycerol outcome. *Curr Opin Clin Nutr Metab Care* 2004;7:145–9.
- [34] Murata M, Ide T, Hara K. Reciprocal responses to dietary diacylglycerol of hepatic enzymes of fatty acid synthesis and oxidation in the rat. *Br J Nutr* 1997;77:107–21.
- [35] Kamphuis MMJW, Mela DJ, Westerterp-Plantenga MS. Diacylglycerols affect substrate oxidation and appetite in humans. *Am J Clin Nutr* 2003;77:1133–9.
- [36] Taguchi H, Watanabe H, Onizawa K, Nagao T, Gotoh N, Yasukawa T, et al. Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. *J Am Coll Nutr* 2000;19:789–96.

Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia—a nuclear magnetic resonance study

Katsunori Ikewaki*, Kenji Noma, Jun-ichiro Tohyama, Toshimi Kido, Seibu Mochizuki

Division of Cardiology, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan

Received 12 December 2003; received in revised form 4 March 2004; accepted 5 March 2004

Available online 23 July 2004

Abstract

Background: Hypertriglyceridemia is often associated with elevated remnants, small dense LDL and decreased HDL-cholesterol (C). The objective of this study was to investigate the efficacy of bezafibrate on lipoprotein subfractions profile and inflammation markers in patients with hypertriglyceridemia.

Methods: Twenty-four hypertriglyceridemic subjects took bezafibrate, 400 mg daily, for 4 weeks. Lipoprotein subclasses were measured by nuclear magnetic resonance (NMR) spectroscopy. Inflammation markers including C-reactive protein (CRP), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) were also determined.

Results: Bezafibrate lowered triglyceride (TG) by 59% and increased HDL-C by 20%. NMR analysis revealed that bezafibrate lowered large TG-rich lipoproteins and IDL by 81% and 46%, respectively. Small LDL was selectively decreased by 53% with increase in large to intermediate LDL, thus altering the LDL distribution towards the larger particles (mean diameter 19.9 to 20.7 nm, $p=0.0001$). Small (HDL1) and intermediate (HDL3) HDL significantly increased by 168% and 70%, whereby resulting in a significant reduction of the mean HDL particle size from 9.0 to 8.7 nm ($p=0.026$). None of inflammation makers showed significant change by bezafibrate.

Conclusions: Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects.

© 2004 Elsevier Ireland Ltd. All rights reserved.

Keywords: Bezafibrate; Lipoprotein; Nuclear magnetic resonance; Triglyceride; Inflammatory marker

1. Introduction

There is a growing body of evidence that, in addition to LDL-cholesterol (C), increased TG-rich lipoproteins (increased remnants), decreased HDL-C and small dense LDL comprise a new cluster of atherogenic dyslipidemia. This type of dyslipidemia represents metabolic perturbations as a consequence of abdominal obesity and involves metabolic abnormalities over entire lipoprotein spectrums and more importantly associates with the increased risk for coronary artery disease (CAD) [1].

Bezafibrate, one of fibrate derivatives, has been considered to be highly effective in treating hypertrigly-

ceridemia and provided a benefit in CAD patients with high TG and low HDL-C levels [2]. Previous studies also revealed that bezafibrate increased HDL-C and altered LDL particles size in favor of decreasing small dense LDL [3,4]. While these studies all employed laborious ultracentrifugation and gradient gel electrophoresis methodologies to quantify lipoprotein subclasses, a new technology utilizing proton nuclear magnetic resonance (NMR) has drawn more attentions recently [5,6]. This new method uses signals emitted from methyl groups of lipids. Overall NMR signals from these lipids were computationally decomposed to yield 16 lipoproteins subclasses concentrations, together with particle numbers and sizes. The NMR method does not require fractionation of lipoproteins, is rapid measurement, and NMR-determined lipoprotein subclasses concentrations correspond well to

* Corresponding author. Tel.: +81 33433 1111; fax: +81 33459 6043.
E-mail address: kikewaki@jikei.ac.jp (K. Ikewaki).

those by the established methods [7]. Furthermore, recent studies [8–10] have shown clinical values of NMR-measured lipoprotein subclasses concentrations as the risk of CAD. In the present study, we, for the first time, utilized NMR method to investigate the effect of bezafibrate on lipoprotein metabolism in hypertriglyceridemic patients. We also focused on potential effects of bezafibrate on inflammatory markers.

2. Methods

Twenty four hypertriglyceridemic patients were recruited for this study from out-patients clinic of Jikei University School of Medicine Hospital. Eligibility criteria included age between 30 and 70 years, body mass index (BMI) less than 30 kg/m² and fasting triglyceride values ≥ 150 mg/dl both at screening and at the end of run-in period. None of the study subjects had poorly controlled diabetes (HbA1c $>8\%$) or evidence of thyroid, liver or renal dysfunction (creatinine >2 mg/dl) and none were taking lipid-modifying medications. All subjects were instructed to maintain their diet, exercise and alcohol intake throughout the study period, including the run-in period. The study was approved by the Ethics Committee of Jikei University School of Medicine. All study subjects gave written informed consent to the study protocol.

After a 4–8-week run-in period, the patients received bezafibrate 200 mg twice daily for 4 weeks. Fasting blood samples (12-h overnight) were drawn from each subject at the end of run-in period and after 4-week bezafibrate treatment into tubes containing N₂EDTA at a final concentration of 0.1%. Plasma was immediately separated by centrifugation (3000 g, 20 min at 4 °C), then plasma concentrations of cholesterol and triglyceride (TG), and HDL-C [11] were freshly measured by the automated enzymatic technique using a Toshiba TBA-80FR auto-analyzer. LDL-C was directly measured using homogeneous enzymatic assay [12] from Daiichi Pure Chemicals (Tokyo, Japan). Plasma apolipoproteins concentrations were quantified using immunoturbidimetric assays [13]. Remnant-like particles (RLP)-C was measured by an immunoseparation technique (Japan Immunoresearch Laboratories, Takasaki, Japan) as reported previously [14]. Aliquots of plasma were stored at -80 °C for the following assays.

Malondialdehyde-modified LDL (MDA-LDL) was measured by ELISA using monoclonal antibody (ML25) as previously described [15]. Interleukin (IL)-6 and monocyte chemotactic protein-1 (MCP-1) levels were measured with an immunoassay using specific monoclonal antibodies (R&D Systems). Measurement of C-reactive protein (CRP) levels was obtained by a high sensitivity latex-enhanced immunonephelometry on the Behring BN II analyzer (Dade Behring) [16]. Frozen plasma was shipped to LipoScience (Raleigh, NC) for proton NMR

analysis as previously reported [6,9]. This new method is based on the signals emitted from methyl group protons of the lipids, which were then calculated by linear least-square method to quantify lipoprotein subclasses lipids concentrations (TG for VLDL, C for IDL, LDL and HDL subclasses). Total of 16 subclasses were simultaneously measured: 6 VLDL subclasses (VLDL6 150 ± 70 nm, VLDL5 70 ± 10 nm, VLDL4 50 ± 10 nm, VLDL3 38 ± 3 nm, VLDL2 33 ± 2 nm, VLDL1 29 ± 2 nm), 4 LDL subclasses (IDL 25 ± 2 nm, LDL3 22 ± 0.7 nm, LDL2 20.5 ± 0.7 nm, LDL1 19 ± 0.7 nm) and 5 HDL subclasses (HDL5 11.5 ± 1.5 nm, HDL4 9.4 ± 0.6 nm, HDL3 8.5 ± 0.3 nm, HDL2 8.0 ± 0.2 nm, HDL1 7.5 ± 0.2 nm). LDL and HDL particle concentrations (nanomoles per liter) are calculated as the sum of LDL subclasses concentrations including IDL for the former and the sum of HDL subclasses for the latter. Average lipoprotein particle sizes were determined by the weighting the mass percentage of each subclass by its diameter. LDL sizes by NMR method closely correlate with those by gradient gel electrophoresis (GGE) method, but are smaller by 5 nm. This resulted in 20.5 nm as a good cutoff point to distinguish individuals with pattern A (mainly large LDL) and pattern B (mainly small LDL), giving a good agreement to the phenotyping by original GGE method.

ApoE phenotype was determined by immunoblot using a specific goat anti-apoE polyclonal antibody as reported previously [17].

Among lipid parameters, TG showed a skewed distribution. Therefore, logarithmically transformed TG values were used for comparison. Changes in biochemical parameters with bezafibrate treatment were analyzed by the paired *t*-test. Distribution of LDL size (patterns A and B) was tested by a chi-square test. Pearson's correlation coefficients were calculated to examine the relationship between lipid parameters. A *p*-value of less than 0.05 with a two-tailed test was considered to be statistically significant. All statistical procedures were performed using SPSS software (version 9.1, SPSS Chicago IL).

3. Results

3.1. Baseline demographic measures

Baseline characteristics of the study subjects are summarized in Table 1. The study subjects were mostly comprised of men (91.7%) and the average age of 53.8 years old. The average BMI of 25.1 kg/m² was equal to the cut-off point to define obesity in Japan and, in fact, 10 patients (42%) were obese. Percentage of hypertension and diabetes are 50% and 25%, respectively. Current smokers comprised 42%. All patients, except for one patient who underwent coronary artery bypass surgery, were free from coronary artery disease evidenced by clinical symptoms, electrocardiogram or laboratory data abnormalities.

3.2. Changes in lipid parameters

Plasma lipids and lipoproteins concentration at baseline and bezafibrate treatment are also listed in Table 1. Descriptive values of total cholesterol ranged from 173 to 391 mg/dl with the mean of 239 mg/dl. Likewise, TG ranged from 150 to 1553 mg/dl with the mean of 427 mg/dl, HDL-C from 25 to 73 mg/dl with the mean of 40.6 mg/dl and LDL-C from 69 to 265 mg/dl with the mean of 124 mg/dl, respectively, thus representing type IV hyperlipoproteinemia as the primary lipid abnormality in the present cohort.

Logarithmically transformed TG negatively correlated with HDL-C, but not LDL-C levels. Bezafibrate significantly reduced total cholesterol, TG and significantly increased HDL-C. In parallel to the changes in lipids, apoC-II, apoC-III and apoE all significantly decreased, whereas apoA-I and apoA-II increased significantly. It should be noted that the magnitudes of change of apoC-III and apoA-II were greater than those of other apolipoproteins.

3.3. Lipoprotein subclasses analysis by NMR

Effects of bezafibrate on lipoprotein subclasses parameters by NMR are summarized in Table 2. Bezafibrate significantly reduced VLDL particles, in particular, large VLDL (VLDL4 to 6) with little effects on relatively small VLDL (VLDL1 to 3). These resulted in a significant reduction of mean VLDL particle size. Although not significant, bezafibrate reduced IDL by 46.4%. Bezafibrate also produced significant increases in large (LDL3) and intermediate (LDL2) LDL, contrasting an effect on small LDL (LDL1) which showed a significant 52.5% decrease. This shift of LDL subclasses distribution was translated into

Table 1
Characteristics of study subjects and changes in lipids with bezafibrate

	Baseline	Bezafibrate	Change (%)
N	24		
Age (years)	53.8±12.7		
Sex (% men)	92%		
BMI (kg/m ²)	25.1±3.1		
Current smoker (%)	42%		
Hypertension (%)	50%		
Diabetes (%)	25%		
TC (mg/dl)	239±51	221±47	-7.7 [†]
TG (mg/dl)	427±321	176±97	-58.8 [†]
HDL-C (mg/dl)	40.6±11.5	48.6±12.5	19.8 [†]
LDL-C (mg/dl)	124±44	139±38	11.4
ApoA-I (mg/dl)	126±24	135±21	6.8*
ApoA-II (mg/dl)	27.1±5.3	36.5±7.6	34.8 [†]
ApoB (mg/dl)	117±25	112±34	-4.0
ApoC-II (mg/dl)	9.9±8.4	6.6±3.4	-33.9*
ApoC-III (mg/dl)	22.9±15.4	12.3±5.9	-46.4 [†]
ApoE (mg/dl)	8.5±6.2	5.4±1.8	-36.5 [†]
RLP-C (mg/dl)	25.5±22.8	9.3±6.0	-63.5*

Values are given as the mean±S.D., except values in percentage.

* $p<0.05$.

[†] $p<0.01$.

[‡] $p<0.001$.

Table 2
Effects of bezafibrate on lipoprotein subclasses parameters by NMR

	Baseline	Bezafibrate	Change (%)
<i>VLDL (mg/dl triglyceride)</i>			
VLDL6 (large)	38.2±60.8	0.7±1.6	-98.2 [†]
VLDL5	128.0±204.2	30.3±49.7	-76.4*
VLDL4	125.4±122.9	63.8±53.4	-49.1 [†]
VLDL3	28.0±40.3	20.1±31.8	-28.3
VLDL2	8.0±9.8	8.5±8.4	7.0
VLDL1 (small)	5.1±7.0	5.6±6.8	10.0
VLDL particle size (nm)	53.6±13.1	44.9±6.9	-16.4 [†]
<i>LDL (mg/dl cholesterol)</i>			
IDL	8.7±9.9	4.6±6.3	-46.4
LDL3 (large)	30.4±48.1	58.0±39.5	90.6*
LDL2	26.4±33.4	47.1±36.9	78.3*
LDL1 (small)	68.2±53.0	32.3±50.5	-52.5*
LDL particle size (nm)	19.9±1.0	20.7±0.7	3.9 [†]
LDL particle number (nmol/l)	1722±629	1643±637	-4.6
<i>LDL phenotype^a</i>			
Pattern A (n)	5	16	$p=0.0014$
Pattern B (n)	19	8	
<i>HDL (mg/dl cholesterol)</i>			
HDL5 (large)	8.3±6.4	7.3±5.5	-11.6
HDL4	10.1±5.9	11.4±5.1	12.9
HDL3	5.8±5.3	9.8±7.4	70.1*
HDL2	15.0±6.0	16.3±6.3	8.3
HDL1 (small)	1.4±3.6	3.7±5.4	167.9*
HDL particle size (nm)	9.0±0.5	8.7±0.4	-3.2*
HDL particle number (μmol/l)	26.9±7.2	34.7±7.4	28.8 [†]

^a The average LDL particle size of 20.5 nm by NMR was used as the cutoff point to distinguish individuals with pattern A (mainly large LDL) and pattern B (mainly small LDL).

Values are given as mean±S.D.

* $p<0.05$.

[†] $p<0.01$.

[‡] $p<0.001$.

a significant increase in particle size as well as a significant decrease of LDL phenotype pattern B. Therefore, 11.7% increase in LDL-C was a product of 3.9% enlargement of particle size and 4.6% reduction of particle number. Bezafibrate caused a selective and significant increase in the levels of intermediate (HDL3) and small (HDL1) HDL. Whereas HDL2, HDL4 and HDL5 did not change significantly by bezafibrate, thus resulting a significant decrease in average HDL particles size and a significant increase in HDL particle number.

3.4. Correlation study using lipoprotein concentrations and particle sizes and their changes after bezafibrate treatment

Fig. 1 illustrates correlation between TG, HDL concentrations and particle sizes. Plasma TG concentration correlated negatively with LDL size, but not with HDL size determined by NMR. HDL-C level showed a signifi-